300267 尔康制药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)0.131-3.9510.928-14.8413.310
总资产报酬率 ROA (%)0.116-3.4460.814-13.0903.168
投入资产回报率 ROIC (%)0.120-3.6060.856-13.7523.038

边际利润分析
销售毛利率 (%)30.37120.42422.22023.34122.781
营业利润率 (%)1.889-11.5930.737-36.6199.134
息税前利润/营业总收入 (%)1.126-11.1511.634-37.6068.990
净利润/营业总收入 (%)1.020-12.4421.982-35.7107.613

收益指标分析
经营活动净收益/利润总额(%)-63.35556.875-66.062-4.14951.442
价值变动净收益/利润总额(%)15.6924.561108.424-2.05061.592
营业外收支净额/利润总额(%)-35.899-3.91720.5963.219-7.969

偿债能力分析
流动比率 (X)2.8892.8692.8833.9013.554
速动比率 (X)1.7081.7231.7502.4682.553
资产负债率 (%)11.97812.21113.74010.27812.300
带息债务/全部投入资本 (%)6.9507.0757.7155.016--
股东权益/带息债务 (%)1,321.0811,295.7901,177.6521,870.7341,255.416
股东权益/负债合计 (%)738.822722.818627.794868.961709.672
利息保障倍数 (X)-4.274-2,082.7662.314-162.26616.962

营运能力分析
应收账款周转天数 (天)31.37224.51530.81143.5070.000
存货周转天数 (天)287.720191.927190.048154.5020.000